FDA Hands Speedy Voucher to Rare Kid Disease Drug
Published Date: 10/9/2026
Notice
Summary
The FDA just gave a special priority review voucher to Ionis Pharmaceuticals for their new rare disease drug, ZANVASTRO, approved on September 3, 2026. This voucher speeds up the review of future drug applications, helping get important medicines to patients faster. This exciting move affects companies working on rare pediatric diseases and could speed up new treatments while boosting innovation.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
ZANVASTRO Approved for Alexander Disease
ZANVASTRO (zilganersen) injection was approved by the FDA on September 3, 2026, and is indicated for the treatment of Alexander disease in pediatric and adult patients.
Priority Review Voucher Issued to Ionis
The FDA issued a priority review voucher to Ionis Pharmaceuticals for ZANVASTRO (zilganersen). ZANVASTRO was approved on September 3, 2026, and the FDA published notice of the voucher award on October 9, 2026.
Section 529 Voucher Authority Noted
The notice reiterates that under section 529 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360ff), the FDA will award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-20768, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA is asking for feedback on the paperwork rules for companies that make biological products, like vaccines. This helps keep everything safe and legal under health laws. If you’re a biologics manufacturer, you’ve got until November 9, 2026, to share your thoughts—no extra costs, just a chance to help shape the process!
Next: 2026-20770, Center For Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in early November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding who gets research funding. Scientists applying for grants in areas like heart health, primate research, and brain studies should note these important review dates.